Evidence map›Paper›PMID 33592317›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2021

Distinguishing SARS-CoV-2 bonafide re-infection from pre-existing minor variant reactivation.

Juliana D Siqueira, Livia R Goes, Brunna M Alves, Ana Carla P da Silva, Pedro S de Carvalho, Claudia Cicala, James Arthos, João P B Viola, Marcelo A Soares

Open access · greenAbstract readCase Reports
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Reinfection in patients with COVID-19: a systematic review.Global health research and policy · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Juliana D SiqueiraPrograma de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
Livia R GoesPrograma de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Brunna M AlvesPrograma de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
Ana Carla P da SilvaHospital do Câncer II, Instituto Nacional de Câncer, Avenida Via Binário do Porto, 831, Rio de Janeiro, RJ 20081-250, Brazil.
Pedro S de CarvalhoPrograma de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
Claudia CicalaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA.
James ArthosLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA.
João P B ViolaPrograma de Imunologia e Biologia de Tumores, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
Marcelo A SoaresPrograma de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Departamento de Genética, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro, RJ 21941-402, Brazil. Electronic address: masoares@inca.gov.br.
Instituto Nacional do Câncer · BRNational Institute of Allergy and Infectious Diseases · USHospital do Câncer III · BR

Funding

The Glycan Shield of the SARS-Cov-2 Spike; Antigenicity and FunctionZIAAI001273 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ARTHOS, JAMES L · 2020 to 2023
$392k
6 · The paper itself

Abstract

Different groups have recently reported events of SARS-CoV-2 reinfection, where patients had a sequence of positive-negative-positive RT-PCR tests. However, such events could be explained by different scenarios such as intermittent viral shedding, bonafide re-infection or multiple infection with alternating predominance of different viruses. Analysis of minor variants is an important tool to distinguish between these scenarios. Using ARTIC network PCR amplification and next-generation sequencing, we obtained SARS-CoV-2 sequences from two timepoints (with a time span of 102 days) of a patient followed at the Brazilian National Cancer Institute. Within-host variant analysis evidenced three single nucleotide variants (SNVs) at the consensus viral sequence in the second timepoint that were already present in the first timepoint as minor variants. Another five SNVs found in the second timepoint were not detected in the first sample sequenced, suggesting an additional infection by a yet another new virus. Our observation shed light into the existence of different viral populations that are present in dynamic frequencies and fluctuate during the course of SARS-CoV-2 infection. The detection of these variants in distinct disease events of an individual highlights a complex interplay between viral reactivation from a pre-existing minority variant and reinfection by a different virus.

Indexed as

Host-Pathogen InteractionsReinfectionSARS-CoV-2AgedBiomarkersComorbidityCOVID-19Disease SusceptibilityFatal OutcomeHumansMaleTomography, X-Ray ComputedViral LoadVirus ActivationBiomarkersIntrahost variationMultiple infectionReactivationRe-infectionSARS-CoV-2

Identifiers

PMID33592317
PMCPMC7882217
OpenAlexW3130277303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.